Earnings summaries and quarterly performance for AVITA Medical.
Executive leadership at AVITA Medical.
Board of directors at AVITA Medical.
Research analysts who have asked questions during AVITA Medical earnings calls.
BO
Brooks O'Neil
Lake Street Capital Markets
4 questions for RCEL
Also covers: ARAY, ATEC, BBNX +11 more
JJ
Joshua Jennings
TD Cowen
3 questions for RCEL
Also covers: ABT, ALUR, ATEC +20 more
CK
Chris Kallos
MST Access
2 questions for RCEL
RO
Ross Osborn
Cantor Fitzgerald
2 questions for RCEL
Also covers: AXGN, CERS, CVRX +12 more
Ryan Zimmerman
BTIG
2 questions for RCEL
Also covers: ALC, GEHC, GKOS +23 more
EA
Eric Anderson
TD Cowen
1 question for RCEL
Also covers: ATEC, CERS, RBOT +2 more
John Hester
Bell Potter Securities
1 question for RCEL
Also covers: MESO, TLX
Lyanne Harrison
Bank of America
1 question for RCEL
Also covers: RMD
MP
Matthew Park
Cantor Fitzgerald
1 question for RCEL
Also covers: AXGN, BVS, CERS +5 more
PD
Phillip Dantoin
Piper Sandler
1 question for RCEL
Also covers: ATEC, CNMD, FNA +2 more
S
Samantha
Piper Sandler & Co.
1 question for RCEL
Also covers: CVRX, SIBN
Recent press releases and 8-K filings for RCEL.
AVITA Medical Provides Preliminary 2025 Results and 2026 Outlook, Secures New Debt Facility
RCEL
Earnings
Guidance Update
Debt Issuance
- AVITA Medical reported preliminary unaudited total net revenues of approximately $17.6 million for the fourth quarter of 2025 and $71.6 million for the full year 2025, representing an 11% increase compared to 2024.
- The company provided a preliminary revenue outlook for fiscal year 2026 in the range of approximately $80 to $85 million, indicating 12% to 19% growth compared to 2025 revenue.
- AVITA Medical refinanced its existing debt, securing a new credit facility with Perceptive Advisors for up to $60 million to strengthen its capital structure and support long-term growth.
- The new credit facility includes trailing twelve-month revenue covenants of $68.5 million for the first quarter ending March 31, 2026, and $73 million for the full year 2026, requiring $15.4 million in revenue for Q1 2026 to meet the initial covenant.
Jan 13, 2026, 1:25 PM
AVITA Medical Reports Q3 2025 Financial Results and Updates Full-Year Guidance
RCEL
Earnings
Guidance Update
Product Launch
Debt Issuance
- AVITA Medical reported Q3 2025 commercial revenue of $17.1 million, representing a 13% decrease compared to the same period in 2024, with a net loss of $13.2 million, or $0.46 per basic and diluted share.
- The company updated its full-year 2025 revenue outlook to a range of $70 million to $74 million, revised down from prior guidance of $76 million to $81 million.
- Operating expenses decreased by 24%, or $7.2 million, to $23.0 million, and net cash use improved to $6.2 million in Q3 2025, with cash, cash equivalents, and marketable securities totaling $23.3 million as of September 30, 2025.
- AVITA Medical received CE Mark approval for RECELL GO® under the EU Medical Device Regulation, enabling its European launch, and amended its credit agreement with OrbiMed, resetting the trailing 12-month revenue covenant to $70.0 million for the quarter ending December 31, 2025.
Nov 6, 2025, 9:12 PM
AVITA Medical Presents Positive RECELL System Data at 2025 Southern Region Burn Conference
RCEL
Product Launch
New Projects/Investments
- AVITA Medical announced two podium presentations at the 2025 Southern Region Burn Conference (SRBC) reinforcing the RECELL System as a standard of care for acute wound treatment.
- A global systematic review of 99 peer-reviewed studies involving over 8,000 patients across 13 countries found RECELL reduces donor site size by up to 97.55%, achieves rapid and reliable wound closure, and demonstrates favorable health economics.
- Real-world U.S. registry data from over 8,500 RECELL-treated patients showed a 36% average shorter hospital stay (5.6-day reduction) and estimated cost savings of over $42,000 per patient compared to traditional split-thickness skin grafts.
Nov 3, 2025, 1:30 PM
AVITA Medical Announces Australian MSAC Recommendation for RECELL in Burn Treatment
RCEL
Product Launch
- AVITA Medical announced that Australia’s Medical Services Advisory Committee (MSAC) has recommended amendments to the Medicare Benefits Schedule (MBS) to include the use of RECELL for treating severe acute burn wounds in adults and children.
- MSAC recognized RECELL as safe and effective, providing benefits such as improved healing, donor site sparing, and reduced hospital stays.
- The committee concluded that RECELL offers superior outcomes in donor site sparing and reduces the need for additional grafting procedures compared to traditional autologous skin grafting.
- RECELL is also acknowledged for its ability to shorten hospital stays, ease patient pain, and minimize scarring.
Oct 28, 2025, 8:30 PM
AVITA Medical's RECELL Receives CMS New Technology Add-on Payment
RCEL
Product Launch
New Projects/Investments
- AVITA Medical's RECELL System is now eligible for New Technology Add-on Payment (NTAP) reimbursement from the Centers for Medicare & Medicaid Services (CMS) for treating acute, non-burn trauma and surgical full-thickness wounds in U.S. hospitals.
- Effective October 1, 2025, this NTAP designation allows hospitals to receive up to $4,875 in supplemental reimbursement per case in addition to standard CMS payments.
- The NTAP aims to ease financial barriers and support broader use of RECELL, and will remain in effect through September 30, 2026.
Oct 1, 2025, 12:30 PM
AVITA Medical Receives CE Mark for RECELL GO, Enabling European Commercialization
RCEL
Product Launch
New Projects/Investments
- AVITA Medical, Inc. (RCEL) has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO, which permits its commercialization in Europe and other markets that recognize the CE Mark.
- RECELL GO is a point-of-care device used by healthcare professionals to prepare a suspension of a patient’s own skin cells (Spray-On Skin™ Cells) to promote healing in burns and traumatic or surgical wounds.
- Data presented at the 2025 European Burns Association Congress demonstrated that adults with deep partial-thickness burns treated with RECELL experienced a 36% reduction in hospital stays compared with traditional grafting.
- AVITA Medical will begin commercialization of RECELL GO in select European countries, including Germany, Italy, and the United Kingdom.
Sep 14, 2025, 11:00 PM
Quarterly earnings call transcripts for AVITA Medical.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more